Melanotan 1 (Afamelanotide): The Approved Tanning Peptide

At a Glance

Melanotan 1 is the rare grey-market peptide with an approved twin. The same molecule, afamelanotide, is sold as Scenesse, a rice-grain-sized implant that porphyria specialists place under the skin of people with erythropoietic protoporphyria (EPP). For these patients a few minutes of sunlight can cause hours to days of burning pain, and the implant lets many of them go outside again.

That makes Melanotan 1 interesting and confusing in equal parts. The approved implant has randomised trials, a label and years of registry data. A vial of “MT-1” bought online has none of that, even if the peptide inside is correct. My view: if you want to understand what afamelanotide does, read the EPP trials. If you want a tan, the evidence is a handful of small studies from the 1990s and 2000s, at much higher doses than people inject today.

How it works

Alpha-MSH binds MC1R on melanocytes and switches pigment production from reddish pheomelanin toward brown-black eumelanin, which absorbs and scatters light. In EPP, protoporphyrin accumulates in the skin and turns visible light into tissue-damaging energy. More eumelanin means less light reaches the protoporphyrin, so the threshold for pain rises [10].

Afamelanotide carries two substitutions (norleucine at position 4, D-phenylalanine at position 7) that make it far more potent and longer-lasting than natural alpha-MSH [6]. Unlike Melanotan 2, it is linear and largely selective for MC1R, which is why erections and strong appetite effects are not part of its profile. Nausea still is.

What the evidence shows

Erythropoietic protoporphyria (the approved use)

The absolute gains in hours look modest on paper. For people who previously avoided daylight altogether, the treatment-continuation data in the registries suggest they matter.

Vitiligo (studied, not approved)

After a four-patient case series [3], a randomised trial in 55 adults with generalised vitiligo added 16 mg implants monthly for 4 months to narrowband UV-B. Repigmentation was faster and greater with the combination (48.6 % vs 33.3 % at day 168), with the clearest benefit in skin types IV to VI [2]. Nausea and minor infections were more common with afamelanotide.

Tanning in healthy volunteers

The original MT-1 studies at the University of Arizona used daily subcutaneous injections. Seven volunteers who received 0.16 mg/kg/day for 10 days tanned at face, neck and forearm sites, with higher skin eumelanin [6]. In three further open-label phase 1 studies, 0.16 mg/kg combined with UV-B or sunlight produced tanning that lasted at least 3 weeks longer than sunlight alone, and the sun-only group needed 50 % more exposure for the same tan [7]. Side effects were nausea and transient facial flushing. These studies were small, open-label and short.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

What stands out: the research doses were about 20 to 40 times higher per injection than the grey-market protocols, and the implant releases 16 mg over weeks. Community protocols at 250–500 mcg come from no trial. They are conventions borrowed from Melanotan 2, a more potent molecule.

For injection technique and reconstitution basics, see the peptide injection guide.

What people report: what works and what doesn’t

Reported to work

• In EPP, the implant lets many patients spend real time outdoors, which matches the trials and the high continuation rates in registries [1][4][5].
• Grey-market users report a gradual, natural-looking tan with UV exposure and less nausea than Melanotan 2 (glp1forum).

Mixed or unclear

• Speed: many users see little colour at 2 weeks and switch to Melanotan 2 out of impatience; others find the nausea and flushing similar to MT-2 (r/Melanotan2).
• No head-to-head comparison of side effects between MT-1 and MT-2 exists.

Reported not to work, or disappointing

• Little or no tan without UV exposure at community doses.
• Nausea for about 10 minutes after injection, facial flushing in the first week, and in one report a flu-like illness after the first doses (r/Melanotan2).
• Darkening of freckles and moles, the same pattern seen with the approved implant.

What a proper trial would need to show for cosmetic use: that low-dose repeated injections produce a meaningful tan without increasing atypical moles over several seasons, compared with sun exposure alone. That trial has not been done.

Implant versus injection: why they are not the same

The approved product and the grey-market vial share a molecule and little else.

• Release profile. Scenesse is a solid, dissolvable implant designed to release 16 mg slowly after it is placed under the skin, so one implant covers about two months. Reconstituted powder injected daily gives short peaks. The trials that established efficacy and safety in EPP used the implant [1]; the daily-injection studies in healthy volunteers used about 11 mg per day for 10 days [6][7]. Community doses of 250–500 mcg per injection sit in neither data set.
• Who places it. The implant is inserted by a trained professional in a recognised centre, after which patients are observed for 30 minutes for allergic reactions [12], and skin checks are built into follow-up. In Germany, porphyria centres such as those in Düsseldorf and Chemnitz contributed patients to the national post-authorisation study [5].
• What is being treated. EPP patients start from a disease that makes light painful. Healthy people seeking a tan start from normal skin, so any risk, however small, buys only a cosmetic effect.
• What is known about the product. The implant has a manufacturing standard, a batch record and a pharmacovigilance system. A research-chemical vial has a label and, at best, a certificate from the seller.

If someone with EPP or suspected EPP is reading this: the route to afamelanotide is a porphyria specialist, not a peptide vendor. Diagnosis needs measurement of protoporphyrin in blood, and the specialist centre can also advise on liver monitoring, which matters in EPP regardless of treatment.

Safety and side effects

From the US label (three randomised trials, 125 patients on afamelanotide vs 119 on vehicle) [11]: implant-site reactions 21 % vs 10 %, nausea 19 % vs 14 %, oropharyngeal pain 7 % vs 5 %, cough, fatigue, skin hyperpigmentation 4 % vs 0 %, dizziness, and melanocytic nevi 4 % vs 2 %. Serious hypersensitivity, including anaphylaxis, has been reported since approval. The label recommends a full-body skin examination twice a year because afamelanotide darkens existing moles and freckles.

The long-term EPP registries have not shown a safety signal beyond mild nausea and pigment changes [4][5]. Those patients are monitored by specialists. Grey-market users are not, and the case-report literature on unregulated alpha-MSH analogues includes changing moles and melanoma, though most of those cases involve Melanotan 2 [8].

Points that apply to anyone considering the molecule:

• People with a history of melanoma, dysplastic nevus syndrome or many atypical moles are poor candidates, because the pigment stimulus acts on moles too.
• Pregnancy and breastfeeding: no adequate data.
• Grey-market powder means unknown content, purity and sterility, no slow-release formulation, and doses chosen by forum convention. Researchers surveying users note that it can be bought online with relative ease [9], which says nothing about whether it is safe.

Legal and regulatory status

• United States. Scenesse (afamelanotide 16 mg implant) was approved by the FDA in 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from EPP, and must be implanted by a trained healthcare professional [11]. Cosmetic tanning is off-label, and powders sold as MT-1 are unapproved drugs.
• EU and Germany. The EMA authorised Scenesse on 22 December 2014 under exceptional circumstances, with additional monitoring and post-authorisation registry studies. It is prescribed only by specialists in recognised EPP centres [12]. Selling MT-1 powder for human use is supply of an unauthorised medicine.
• Sport. Afamelanotide is not named on the WADA 2026 Prohibited List, and as an approved medicine it does not fall under the S0 catch-all for non-approved substances. Athletes should still confirm with their national anti-doping organisation.

How it fits

Afamelanotide is the most thoroughly studied melanocortin peptide for skin. If the question is “which tanning peptide has real human data”, this is the answer, with the caveat that the data come from patients with a rare disease using an implant, not from healthy people injecting powder.

Related Articles

• Melanotan 2: Tanning Peptide, Real Risks, No Approval
• PT-141 (Bremelanotide): Evidence and Uses
• GHK-Cu for Skin: Anti-Aging Evidence and Protocols
• Peptide Injection Guide
• Peptide Sourcing: Quality and Grey-Market Risks